Data as of Jul 25
| -0.94 / -3.94%|
The 6 analysts offering 12-month price forecasts for Theravance Inc have a median target of 28.00, with a high estimate of 47.00 and a low estimate of 7.00. The median estimate represents a +22.06% increase from the last price of 22.94.
The current consensus among 7 polled investment analysts is to Hold stock in Theravance Inc. This rating has held steady since July, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.